LYRA THERAPEUTICS, INC.

Analyst Reco. Lyra Therapeutics, Inc.

Equities

LYRA

US55234L1052

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-14 pm EDT			5-day change	1st Jan Change
0.2952 ^USD	-4.80%		-7.87%	-94.37%

May. 21	Lyra Therapeutics Reduces Workforce to Extend Cash Runway	MT
May. 21	Lyra Therapeutics, Inc. Announces Termination of John E. Bishop as Chief Technology Officer, Effective on or About June 20, 2024	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50	May. 07	MT
HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy	May. 07	MT
BTIG Assumes Lyra Therapeutics at Buy With $15 Price Target	23-10-06	MT
BofA Securities Increases Price Target on Lyra Therapeutics to $15 From $13, Maintains Buy Rating	23-09-12	MT
HC Wainwright Starts Lyra Therapeutics at Buy With $12 Price Target	23-08-31	MT
BTIG Adjusts Price Target on Lyra Therapeutics to $20 From $24, Maintains Buy Rating	23-02-07	MT
Cantor Fitzgerald Starts Lyra Therapeutics at Overweight With $15 Price Target	22-05-24	MT
LYRA THERAPEUTICS : BofA securities Adjusts Lyra Therapeutics PT to $26 From $19, Maintains Buy Rating	20-12-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer